GPC1 and cancer: By optimizing the hinge and transmembrane domains of the nanobody (D4)-based CAR, we have a potent lead GPC1 CAR T candidate that rapidly eliminates low GPC1-expressing xenografts which provides the opportunity for clinical applications in GPC1-positive cancers.